Quest for the right Drug
צפורוקסים - פרזניוס 750 מ"ג CEFUROXIME - FRESENIUS 750 MG (CEFUROXIME AS SODIUM SALT)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-שרירי, תוך-ורידי : I.M, I.V
צורת מינון:
אין פרטים : POWDER FOR SOLUTION OR SUSPENSION FOR INJECTION OR INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Pharmaceutical particulars : מידע רוקחי
6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients None 6.2 Incompatibilities This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6. 6.3 Shelf life Dry Powder The expiry date of the product is indicated on the packaging materials. After reconstitution : Chemical and physical in -use stability has been demonstrated for 5 hours at 2°C to 8°C From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. 6.4 Special precautions for storage Store below 25 °C. Keep the vial in the outer carton in order to protect from light. For storage conditions after reconstitution of the medicinal product, see section 6.3. 6.5 Nature and contents of container Cefuroxime -Fresenius 750 mg 15 ml glass vial with rubber stopper covered with aluminium seals with plastic flip -off caps. Cefuroxime -Fresenius 1500 mg 20 ml glass vial with rubber stopper covered with aluminium seals with plastic flip -off caps. 6.6 Special precautions for disposal and other handling Cefuroxime -Fresenius 750 mg Instructions for reconstitution Table 4. Addition volumes and concentrations which may be useful when fractional doses are required. Addition volumes and solution/suspension concentrations, which may be useful when fractional doses are required Approximate Vial size Amount of water to be cefuroxime Resulting added (ml) concentration Product )mg/ml) ** 750 mg Intramuscular 3 mL 216 Suspension intravenous at least 6 mL 116 Solution bolus intravenous at least 6 mL* 116 Solution infusion * Reconstituted solution to be added to 50 or 100 mL of compatible infusion fluid (see information on compatibility, below) ** The resulting volume of the solution of cefuroxime in reconstitution medium is increased due the displacement factor of the drug substance resulting in the listed concentrations in mg/mL As for all parenteral medicinal products, inspect the reconstituted solution or suspension visually for particulate matter and discoloration prior to administration. Intramuscular injection: After addition of the specified amount of diluent for intramuscular injection, a suspension is formed. Intravenous bolus injection or intravenous infusion: The solution should only be used if the solution is clear and practically free from particles. Solutions and suspensions range in colour from clear to yellow coloured depending on concentration, diluent and storage conditions used. Preparation of solution for intravenous infusion Cefuroxime 750 mg should be reconstituted following the instructions for reconstitution of intravenous injection with water for injection (see table 4 above). Further dilution should take place in 50-100 ml of one of the following compatible infusion fluids prior to intravenous infusion administration: Cefuroxime sodium is compatible with the following infusion fluids. It will remain potency for up to 5 hours at 2°C to 8°C in: − water for injections − 0.9 % sodium chloride solution For single use only Any unused product or waste material should be disposed of in accordance with local requirement Cefuroxime -Fresenius 1500 mg Instructions for reconstitution Table5 . Addition volumes and solution concentrations, which may be useful when fractional doses are required Addition volumes and concentrations, which may be useful when fractional doses are required Vial size Amount of water to be Approximate Resulting product added (ml) cefuroxime concentration (mg/mL) ** 1.5 g intravenous at least 15mL 94 Solution bolus intravenous infusion 15 mL* 94 Solution *Reconstituted solution to be added to 50 or 100 ml of compatible infusion fluid (see information on compatibility, below) * The resulting volume of the solution of cefuroxime in reconstitution medium is increased due the displacement factor of the drug substance resulting in the listed concentrations in mg/ml. As for all parenteral medicinal products, inspect the reconstituted solution visually for particulate matter and discoloration prior to administration. Intravenous bolus injection or intravenous infusion: The solution should only be used if the solution is clear and practically free from particles. Solutions range in colour from clear to yellow coloured depending on concentration, diluent and storage conditions used. Preparation of solution for intravenous infusion Cefuroxime 1500 mg should be reconstituted following the instructions for reconstitution of intravenous injection with water for injection (see table 5 above). Further dilution should take place in 50-100 ml of one of the following compatible infusion fluids prior to intravenous infusion administration: Cefuroxime sodium is compatible with the following infusion fluids. It will remain potency for up to 5 hours at 2°C to 8°C in: water for injections 0.9 % sodium chloride solution For single use only Any unused product or waste material should be disposed of in accordance with local requirements. 7 MANUFACTURER: Labesfal - Laboratorios Almiro S.A Fresenius Kabi Group Lagedo, 3465-157 Santiago De Besteiros, Portugal
שימוש לפי פנקס קופ''ח כללית 1994
התרופה תימצא רק בבתי חולים ותנופק לחולים אמבולטורים רק באמצעותם
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה אשפוזית לפי החלטת משרד הבריאות
מידע נוסף